Want to see TSE:APLI full AI Analyst Report?
APLI Stock Chart & Stats
C$0.02
>-C$0.01(-14.29%)
At close: 4:00 PM EST
C$0.02
>-C$0.01(-14.29%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume36.33K
Average Volume (3M)72.91K
Market Cap
C$1.99M
Enterprise ValueC$14.17M
Total Cash (Recent Filing)C$40.00K
Total Debt (Recent Filing)C$12.94M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding132,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Infectious-disease PipelineA narrow, clinical-stage focus on unmet infectious-disease indications creates durable strategic clarity. Specialization can improve R&D efficiency, make the company an attractive partner/licensing target, and align it with persistent public-health and funding priorities for antibacterials, antivirals, and antifungals.
Very High Gross Profit MarginsConsistently very high gross margins imply strong unit economics when product revenues scale. This structural margin profile supports profitable product commercialization or high-value licensing deals, improving long-term earnings potential once R&D converts to commercial sales or partnered revenue.
Improving Cash-burn TrendA meaningful reduction in cash burn and a 2025 positive operating cash flow year indicate management can materially cut or manage spend. Sustained improvement reduces near-term financing pressure and extends runway, giving more time for clinical milestones to unlock durable funding or partnerships.
Bears Say
Strained Balance SheetNegative equity and rising debt materially weaken financial flexibility. Over time this increases financing costs, raises default or covenant risk, and makes the company reliant on dilutive financing or expensive borrowing, constraining its ability to fund development without external support.
Recurring Negative Operating Cash FlowPersistent negative operating and free cash flow point to structural funding needs. Reliance on external capital raises dilution and execution risk, and recurring negative cash generation undermines the company's capacity to self-finance trials or commercial launches over the medium term.
Ongoing Net Losses And Volatile, Low RevenueChronic unprofitability and volatile low revenue reduce strategic optionality. Without stable, scalable revenue, the company faces continuous funding needs, limited reinvestment capacity, and higher likelihood of dilution or partnership dependence to advance clinical programs long-term.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$1.99M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Aug 07, 2026 which is in 25 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Jun 27, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).